

Composition and Method for Enhancing Fibrinolysis

Abstract

The present invention relates to a novel alpha-2-antiplasmin-binding molecules and treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient which comprises administering an alpha-2-antiplasmin-binding molecule capable of preventing inhibition of plasmin by endogenous alpha-2-antiplasmin. The invention also relates to a treatment for pulmonary embolism, myocardial infarction, thrombosis or stroke in a patient comprising coadministering an alpha-2-antiplasmin-binding molecule of the invention together with a thrombolytic agent.

A139-04.WPD

10
15